Osmetech, Fisher Healthcare Terminate Distribution Deal | GenomeWeb

NEW YORK (GenomeWeb News) – Osmetech today said that its US distribution agreement with Thermo Fisher's Fisher Healthcare, which was signed earlier this year, has been terminated.

According to the UK-based molecular diagnostics firm, the firms mutually agreed to terminate the five-year contract, which was signed at the end of March.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.

At Nature, John Wilbanks and Eric Topol call for openness in health data.

Law.com predicts that genomic and genetic testing will become common in toxic tort cases.

A Pew Research Center report finds that most Americans are wary of using technologies like gene editing to enhance human abilities.